Cited by 78Diabetes, Cardiovascular Risks, and LipoproteinsLipid metabolism and disordersLipoproteins and Cardiovascular Health

The DOI matches its Crossref record; 269 of the 269 references it cites were found in a registry or an index.

Modification of lipoprotein metabolism and function driving atherogenesis in diabetes

Open access

Luciani, Lorenzo, Pedrelli, Matteo, Parini, Paolo·2024·Atherosclerosis

DOI 10.1016/j.atherosclerosis.2024.117545

Open this paper in CoChat — free account Open PDF

Abstract

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease, characterized by raised blood glucose levels and impaired lipid metabolism resulting from insulin resistance and relative insulin deficiency. In diabetes, the peculiar plasma lipoprotein phenotype, consisting in higher levels of apolipoprotein B-containing lipoproteins, hypertriglyceridemia, low levels of HDL cholesterol, elevated number of small, dense LDL, and increased non-HDL cholesterol, results from an increased synthesis and impaired clearance of triglyceride rich lipoproteins. This condition accelerates the development of the atherosclerotic cardiovascular disease (ASCVD), the most common cause of death in T2DM patients. Here, we review the alteration of structure, functions, and distribution of circulating lipoproteins and the pathophysiological mechanisms that induce these modifications in T2DM. The review analyzes the influence of diabetes-associated metabolic imbalances throughout the entire process of the atherosclerotic plaque formation, from lipoprotein synthesis to potential plaque destabilization. Addressing the different pathophysiological mechanisms, we suggest improved approaches for assessing the risk of adverse cardiovascular events and clinical strategies to reduce cardiovascular risk in T2DM and cardiometabolic diseases.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.atherosclerosis.2024.117545

Cites

269 of 269 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Items 201–269 of 269

Glycosylphosphatidylinositol‐anchored high‐density lipoprotein‐binding protein 1 and the intravascular processing of triglyceride‐rich lipoproteins
Adeyo, O., Goulbourne, C. N., Bensadoun, A., Beigneux, A. P., Fong, L. G., & Young, S. G. (2012) · Journal of Internal Medicine · doi:10.1111/joim.12003 · Cited by 48
Glycation of low‐density lipoprotein results in the time‐dependent accumulation of cholesteryl esters and apolipoprotein B‐100 protein in primary human monocyte‐derived macrophages
Brown, B. E., Rashid, I., van Reyk, D. M., & Davies, M. J. (2007) · FEBS Journal · doi:10.1111/j.1742-4658.2007.05699.x · Cited by 47
Circulating PCSK9 in patients with type 2 diabetes and related metabolic disorders
Ibarretxe, D., Girona, J., Plana, N., Cabré, A., Ferré, R., Amigó, N., Guaita, S., Mallol, R., Heras, M., & Masana, L. (2015) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2015.11.001 · Cited by 47
Saroglitazar, a Dual PPAR α/γ Agonist, Improves Atherogenic Dyslipidemia in Patients With Non-Cirrhotic Nonalcoholic Fatty Liver Disease: A Pooled Analysis
Siddiqui, M. S., Parmar, D., Sheikh, F., Sarin, S. K., Cisneros, L., Gawrieh, S., Momin, T., Duseja, A. K., & Sanyal, A. J. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.01.018 · Cited by 47
Glycation of Apolipoprotein C1 Impairs Its CETP Inhibitory Property: Pathophysiological Relevance in Patients With Type 1 and Type 2 Diabetes
Bouillet, B., Gautier, T., Blache, D., de Barros, J.-P. P., Duvillard, L., Petit, J., Lagrost, L., & Vergès, B. L. (2014) · Diabetes Care · doi:10.2337/dc13-1467 · Cited by 46
Significant improvement of apolipoprotein B-containing lipoprotein metabolism by insulin treatment in patients with non-insulin-dependent diabetes mellitus
Duvillard, L., Pont, F., Florentin, E., Gambert, P., & Vergès, B. L. (2000) · Diabetologia · doi:10.1007/s001250050004 · Cited by 45
Hydrazine compounds inhibit glycation of low-density lipoproteins and prevent the in vitro formation of model foam cells from glycolaldehyde-modified low-density lipoproteins
Brown, B. E., Mahroof, F. M., Cook, N. L., van Reyk, D. M., & Davies, M. J. (2006) · Diabetologia · doi:10.1007/s00125-006-0137-3 · Cited by 45
Small-dense LDL and LDL glycation in metabolic syndrome and in statin-treated and non-statin-treated type 2 diabetes
Younis, N. N., Soran, H., Sharma, R., Charlton-Menys, V., Greenstein, A. S., Elseweidy, M. M., & Durrington, P. N. (2010) · Diabetes and Vascular Disease Research · doi:10.1177/1479164110383063 · Cited by 45
Subclasses of Low-Density Lipoprotein and Very Low-Density Lipoprotein in Familial Combined Hyperlipidemia: Relationship to Multiple Lipoprotein Phenotype
Georgieva, A. M., van Greevenbroek, M. M. J., Krauss, R. M., Brouwers, M. C. G. J., Vermeulen, V. M. M.-J., Robertus-Teunissen, M. G., Kallen, C., & de Bruin, T. W. (2004) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000119681.47218.a4 · Cited by 45
Caffeic acid attenuates the inflammatory stress induced by glycated LDL in human endothelial cells by mechanisms involving inhibition of AGE‐receptor, oxidative, and endoplasmic reticulum stress
Toma, L., Sanda, G. M., Niculescu, L. S., Deleanu, M., Stancu, C. S., & Sima, A. V. (2017) · BioFactors · doi:10.1002/biof.1373 · Cited by 45
Glycation of LDL: AGEs, impact on lipoprotein function, and involvement in atherosclerosis
Poznyak, A. V., Sukhorukov, V. N., Surkova, R., Orekhov, N. A., & Orekhov, A. N. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1094188 · Cited by 45
Postprandial chylomicrons and adipose tissue lipoprotein lipase are altered in type 2 diabetes independently of obesity and whole-body insulin resistance
Annuzzi, G., Giacco, R., Patti, L., Di Marino, L., De Natale, C., Costabile, G., Marra, M., Santangelo, C., Masella, R., & Rivellese, A. A. (2008) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2007.12.003 · Cited by 45
Impaired Cholesterol Efflux Capacity of High-Density Lipoprotein Isolated From Interstitial Fluid in Type 2 Diabetes Mellitus—Brief Report
Apro, J., Tietge, U. J. F., Dikkers, A., Parini, P., Angelin, B., & Rudling, M. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.116.307385 · Cited by 44
Self-citation
Glycoxidized low-density lipoprotein regulates the expression of scavenger receptors in THP-1 macrophages
Lam, M. C., Tan, K. C. B., & Lam, K. S. L. (2004) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2004.08.003 · Cited by 43
Impairment of mitochondrial respiratory chain activity in aortic endothelial cells induced by glycated low-density lipoprotein
Sangle, G. V., Chowdhury, S. R., Xie, X., Stelmack, G. L., Halayko, A. J., & Shen, G. X. (2009) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.12.017 · Cited by 43
Roles of hepatic lipase and cholesteryl ester transfer protein in determining low density lipoprotein subfraction distribution in Chinese patients with non-insulin-dependent diabetes mellitus
Tan, K. C. B., Shiu, S. W. M., & Chu, B. (1999) · Atherosclerosis · doi:10.1016/s0021-9150(99)00077-5 · Cited by 42
A Comparative Study of Cultured Smooth Muscle Cell Proliferation and Injury, Utilizing Glycated Low Density Lipoproteins with Slight Oxidation, Auto-oxidation, or Extensive Oxidation
Taguchi, S., Oinuma, T., & Yamada, T. (2000) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat1994.7.132 · Cited by 42
Blood lipids in 75,048 type 2 diabetic patients: a population-based survey from the Swedish National diabetes register
Eriksson, M., Zethelius, B., Eeg‐Olofsson, K., Nilsson, P. M., Guðbjörnsdóttir, S., Cederholm, J., & Eliasson, B. (2010) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/hjr.0b013e32833ba61e · Cited by 42
SULF2 strongly prediposes to fasting and postprandial triglycerides in patients with obesity and type 2 diabetes mellitus
Hassing, H. C., Surendran, R. P., Derudas, B., Verrijken, A., Francque, S., Mooij, H. L., Moens, S. J. B., Hart, L. M. ‘., Nijpels, G., Dekker, J. M., et al. (2013) · Obesity · doi:10.1002/oby.20682 · Cited by 41
Triglyceride-Rich Lipoproteins Modulate the Distribution and Extravasation of Ly6C/Gr1low Monocytes
Saja, M. F., Baudino, L., Jackson, W. D., Cook, H. T., Malik, T. H., Fossati‐Jimack, L., Ruseva, M. M., Pickering, M. C., Woollard, K. J., & Botto, M. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.08.020 · Cited by 41
Apolipoprotein B Secretion Is Regulated by Hepatic Triglyceride, and Not Insulin, in a Model of Increased Hepatic Insulin Signaling
Moon, B. C., Hernández‐Ono, A., Stiles, B. L., Wu, H., & Ginsberg, H. N. (2011) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.111.241356 · Cited by 41
Activation of protease calpain by oxidized and glycated LDL increases the degradation of endothelial nitric oxide synthase
Dong, Y., Wu, Y., Wu, M., Wang, S., Zhang, J., Xie, Z., Xu, J., Song, P., Wilson, K., Zhao, Z., et al. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00416.x · Cited by 40
Epitopes close to the apolipoprotein B low density lipoprotein receptor-binding site are modified by advanced glycation end products
Wang, X., Bucala, R., & Milne, R. W. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7643 · Cited by 40
Role of the Gut in Diabetic Dyslipidemia
Stahel, P., Xiao, C., Nahmias, A., & Lewis, G. F. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00116 · Cited by 39
Plasma proprotein convertase subtilisin–kexin type 9 does not change during 24h insulin infusion in healthy subjects and type 2 diabetic patients
Kappelle, P. J. W. H., Lambert, G. C., & Dullaart, R. P. F. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.10.028 · Cited by 37
Angiopoietin-Like Protein 4 is Differentially Regulated by Glucocorticoids and Insulin in vitro and in vivo in Healthy Humans
van Raalte, D. H., Brands, M., Serlie, M. J. M., Mudde, K., Stienstra, R., Sauerwein, H. P., Kersten, S., & Diamant, M. (2012) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0032-1321864 · Cited by 37
Glycated LDL increase VCAM-1 expression and secretion in endothelial cells and promote monocyte adhesion through mechanisms involving endoplasmic reticulum stress
Toma, L., Sanda, G. M., Deleanu, M., Stancu, C. S., & Sima, A. V. (2016) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-016-2724-z · Cited by 36
Cardiometabolic Medicine: Development of a New Subspecialty
Saxon, D. R., Reiter–Brennan, C., Blaha, M. J., & Eckel, R. H. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa261 · Cited by 36
Insulin inhibition of apolipoprotein B mRNA translation is mediated via the PI-3 kinase/mTOR signaling cascade but does not involve internal ribosomal entry site (IRES) initiation
Sidiropoulos, K. G., Meshkani, R., Avramoglu, R. K., & Adeli, K. (2007) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2007.06.029 · Cited by 36
Non-enzymatic glycation of lipoprotein(a) in vitro and in vivo
Doucet, C. (1995) · Atherosclerosis · doi:10.1016/0021-9150(95)05600-2 · Cited by 35
Role of Nε-(Carboxymethyl)Lysine in the Development of Ischemic Heart Disease in Type 2 Diabetes Mellitus
Ahmed, K. A., Muniandy, S., & Ismail, I. S. (2007) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.2007014 · Cited by 35
Involvement of Heat Shock Factor-1 in Glycated LDL–Induced Upregulation of Plasminogen Activator Inhibitor-1 in Vascular Endothelial Cells
Zhao, R., & Shen, G. X. (2007) · Diabetes · doi:10.2337/db06-1199 · Cited by 35
Impact of Diabetes-Associated Lipoproteins on Generation of Fibrinolytic Regulators from Vascular Endothelial Cells
Ren, S., Lee, H., Hu, L., Lü, L., & Shen, G. X. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.1.286 · Cited by 34
Glycated LDL Concentrations in Non-Diabetic and Diabetic Subjects Measured with Monoclonal Antibodies Reactive with Glycated Apolipoprotein B Epitopes
Cohen, M. P., Lautenslager, G. T., & Shea, E. A. (1993) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.1993.31.11.707 · Cited by 34
High-Density Lipoprotein Subspecies in Health and Human Disease: Focus on Type 2 Diabetes
Davidson, W. S., & SHAH, A. S. (2019) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcj-15-1-55 · Cited by 33
Thin-Cap Fibroatheroma Rather Than Any Lipid Plaques Increases the Risk of Cardiovascular Events in Diabetic Patients: Insights From the COMBINE OCT–FFR Trial
Fabris, E., Berta, B., Roleder, T., Hermanides, R. S., Ijsselmuiden, A. J. J., Kauer, F., Alfonso, F., von Birgelen, C., Escaned, J., Camaro, C., et al. (2022) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.121.011728 · Cited by 32
Plasma proprotein convertase subtilisin/kexin type 9 is associated with Lp(a) in type 2 diabetic patients
Nekaies, Y., Baudin, B., Kelbousi, S., Sakly, M., & Attia, N. (2015) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2015.08.003 · Cited by 31
Lipoprotein Molecules, Cholesterol and Atherosclerosis In Diabetes Mellitus
Barach, J. H., & Lowy, A. (1952) · Diabetes · doi:10.2337/diab.1.6.441 · Cited by 31
Obesity is associated with an altered HDL subspecies profile among adolescents with metabolic disease
Davidson, W. S., Heink, A., Sexmith, H., Dolan, L. M., Gordon, S. M., Otvos, J. D., Melchior, J., Elder, D. A., Khoury, J. C., Geh, E. N., et al. (2017) · Journal of Lipid Research · doi:10.1194/jlr.m078667 · Cited by 30
Postprandial metabolism of apolipoproteins B48, B100, C-III, and E in humans with APOC3 loss-of-function mutations
Taskinen, M., Björnson, E., Matikainen, N., Söderlund, S., Rämö, J. T., Ainola, M., Hakkarainen, A., Sihlbom, C., Thorsell, A., Andersson, L. K., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.160607 · Cited by 30
HDL2 interferes with LDL association with arterial proteoglycans: A possible athero-protective effect
Umaerus, M., Rosengren, B. E., Fagerberg, B., Hurt‐Camejo, E., & Camejo, G. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.08.040 · Cited by 30
Glycation of plasma low density lipoproteins increases interaction with arterial proteoglycans
Edwards, I. J., Wagner, J. D., Litwak, K. N., Rudel, L. L., & Cefalu, W. T. (1999) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(99)00074-1 · Cited by 30
Cholesterol not particle concentration mediates the atherogenic risk conferred by apolipoprotein B particles: a Mendelian randomization analysis
Helgadottir, A., Thorleifsson, G., Snaebjarnarson, A., Stefansdottir, L., Sveinbjornsson, G., Tragante, V., Björnsson, E., Steinthorsdottir, V., Gretarsdottir, S., Helgason, H., et al. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwac219 · Cited by 30
Evolution of Type 2 Diabetes Management from a Glucocentric Approach to Cardio-Renal Risk Reduction: The New Paradigm of Care
Jacob, S., Krentz, A. J., Deanfield, J. E., & Rydén, L. (2021) · Drugs · doi:10.1007/s40265-021-01554-6 · Cited by 29
Fatty acid-induced atherogenic changes in extracellular matrix proteoglycans
Rodrı́guez-Lee, M., Bondjers, G., & Camejo, G. (2007) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3282ef534f · Cited by 27
Lipoprotein-matrix interactions in macrovascular disease in diabetes
Lisa, R. (2004) · Frontiers in bioscience · doi:10.2741/1248 · Cited by 26
Triglyceride-Rich Lipoprotein Regulates APOB48 Receptor Gene Expression in Human THP-1 Monocytes and Macrophages3
Bermúdez, B., López, S., Varela, L. M., Ortega‐Gómez, A., Pacheco, Y. M., Moreda, W., Moreno‐Luna, R., Abia, R., & Muriana, F. J. G. (2011) · Journal of Nutrition · doi:10.3945/jn.111.149963 · Cited by 26
Monocyte and macrophage foam cells in diabetes-accelerated atherosclerosis
Cervantes, J., & Kanter, J. E. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1213177 · Cited by 24
Postprandial dyslipidemia after a standardized high-fat meal in BMI-matched healthy individuals, and in subjects with prediabetes or type 2 diabetes
Lim, S. K., Kim, Y. J., Khang, A. R., & Eckel, R. H. (2021) · Clinical Nutrition · doi:10.1016/j.clnu.2021.09.004 · Cited by 23
Use of Apolipoprotein B in the Era of Precision Medicine: Time for a Paradigm Change?
Cole, J., Zubirán, R., Wolska, A. T., Jialal, I., & Remaley, A. T. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12175737 · Cited by 23
Pathophysiology of type 2 diabetes mellitus
Yki‐Järvinen, H. (2011) · doi:10.1093/med/9780199235292.003.1336 · Cited by 22
Postprandial dyslipidemia in insulin resistant states in adolescent populations
Higgins, V., & Adeli, K. (2020) · Journal of Biomedical Research · doi:10.7555/jbr.34.20190094 · Cited by 20
Long-term prognostic utility of low-density lipoprotein (LDL) triglyceride in real-world patients with coronary artery disease and diabetes or prediabetes
Jin, J., Zhang, H., Cao, Y., Liu, H., Hua, Q., Li, Y., Zhang, Y., Guo, Y., Wu, N., Zhu, C., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01125-1 · Cited by 20
IDL can stimulate atherogenic gene expression in cultured human vascular endothelial cells
Maeno, Y., Kashiwagi, A., Nishio, Y., Takahara, N., & Kikkawa, R. (2000) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(99)00147-3 · Cited by 19
Basal and insulin-regulated VLDL1 and VLDL2 kinetics in men with type 2 diabetes
Johansen, R. F., Søndergaard, E., Sørensen, L. P., Jurik, A. G., Christiansen, J. S., & Nielsen, S. (2016) · Diabetologia · doi:10.1007/s00125-015-3856-5 · Cited by 19
Beyond LDL-c: The importance of serum oxidized LDL in predicting risk for type 2 diabetes in the middle-aged Asian Indians
Banerjee, J., Mishra, N., Damle, G., & Dhas, Y. (2018) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2018.08.036 · Cited by 17
LDL Transcytosis by the Arterial Endothelium—Atherosclerosis by a Thousand Cuts?
Ho, T. W. W., Henry, A., & Lee, W. L. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01118-x · Cited by 17
Non–High-Density Lipoprotein Cholesterol and Guidelines for Cholesterol Lowering in Recent History
Levinson, S. S. (2019) · Laboratory Medicine · doi:10.1093/labmed/lmz032 · Cited by 15
Increased Plasma Glycated Low-Density Lipoprotein Concentrations in Diabetes: A Marker of Atherogenic Risk
Cohen, M. P., Jin, Y., & Lautenslager, G. T. (2004) · Diabetes Technology & Therapeutics · doi:10.1089/152091504774198043 · Cited by 15
Impact of glycated LDL on endothelial nitric oxide synthase in vascular endothelial cells: involvement of transmembrane signaling and endoplasmic reticulum stress
Nair, M. M., Zhao, R., Xie, X., & Shen, G. X. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.01.008 · Cited by 14
Lysophospholipids: Effectors mediating the contribution of dyslipidemia to calcification associated with atherosclerosis
Camejo, G. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.02.005 · Cited by 13
Association of HDL Subfraction Profile with the Progression of Insulin Resistance
Pikó, P., Jenei, T., Kósa, Z., Sándor, J., Kovács, N., Seres, I., Paragh, G., & Ádány, R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713563 · Cited by 12
Scavenger Receptor a Mediates Glycated LDL Transcytosis Across Endothelial Cells to Promote Atherosclerosis
Cheng, W., Shu, M., Kuang, L., Bai, X., Jia, X., Zhao, Y., Lu, Y., Zhu, L., Wang, L., Zhu, Y., et al. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.123836 · Cited by 10
Classification and diagnosis of diabetes mellitus
Alberti, K. G. M. M., & Zimmet, P. (2011) · doi:10.1093/med/9780199235292.003.1304 · Cited by 8
Carbamylated lipoproteins in diabetes
Denimal, D. (2023) · World Journal of Diabetes · doi:10.4239/wjd.v14.i3.159 · Cited by 6
Lipoprotein metabolism
Angelin, B., & Parini, P. (2011) · doi:10.1093/med/9780199235292.003.1233 · Cited by 6
Self-citation
Levels of atherogenic lipoproteins are unexpectedly reduced in interstitial fluid from type 2 diabetes patients
Apro, J., Parini, P., Bröijersén, A., Angelin, B., & Rudling, M. J. (2015) · Journal of Lipid Research · doi:10.1194/jlr.p058842 · Cited by 5
Self-citation
Plasma insulin is required for the increase in plasma angiopoietin‐like protein 8 in response to nutrient ingestion
Abu‐Farha, M., Alatrach, M., Abubaker, J. A., Al‐Khairi, I., Cherian, P., Agyin, K., Abdelgani, S., Norton, L., Adams, J., Alsaeed, D., et al. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3643 · Cited by 4
Plasma apolipoproteins AI, AII, B, CI, and E are glucosylated in hyperglycemic diabetic subjects
Curtiss, L. K., & Witztum, J. L. (1985) · Diabetes · doi:10.2337/diabetes.34.5.452

Sorted by citations

Metabolic syndrome
Neeland, I. J., Lim, S., Tchernof, A., Gastaldelli, A., Rangaswami, J., Ndumele, C. E., Powell-Wiley, T. M., & Després, J.-P. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00563-5 · Cited by 463
“Athero-genic dyslipidaemia, inflammatory cytokines, ROS and immune cells are also involved in formation of atheromatous plaques 132–135 .”
Nutrition and Lifestyle Interventions in Managing Dyslipidemia and Cardiometabolic Risk
Berisha, H., Hattab, R., Comi, L., Giglione, C., Migliaccio, S., & Magni, P. (2025) · Nutrients · doi:10.3390/nu17050776 · Cited by 85
“…TG and reduced HDL-C levels, which are hallmark features of metabolic syndrome and associated with increased cardiovascular risk [32]. characterized by elevated TG and reduced HDL-C levels, which are hallmark features of metabolic syndrome and associated with increased cardiovascular risk [32].”
The link between diabetes and cardiovascular disease
Borén, J., Öörni, K., & Catapano, A. L. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117607 · Cited by 44
[Incisional hernia after surgery for abdominal aortic aneurysm].
Augestad, K. M., Wilsgaard, T., & Solberg, S. K. (2002) · PubMed · Cited by 29
Association of insulin resistance-related indicators with cardiovascular disease in Chinese people with different glycemic states
Zhang, Z., & Tan, L. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1515559 · Cited by 25

See all 78

Authors: Luciani, L., Pedrelli, M., & Parini, P.
Affiliations: Scuola Superiore Sant'Anna (IT)
Karolinska University Hospital (SE)
Corresponding author: Parini, Paolo
ORCID: Pedrelli, Matteo
Parini, Paolo
Venue: Atherosclerosis
Publisher: Elsevier BV
Published: 2024-07
Volume: 394
Pages: 117545
ISSN: 0021-9150 (ISSN-L)
DOI: 10.1016/j.atherosclerosis.2024.117545
OpenAlex: W4394875384
Cited by: 72
References: 268
Citations by year: 2026: 30 · 2025: 32 · 2024: 9
FWCI: 4.17
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
creativecommons.org/licenses/by/4.0/ (vor)
Locations: Atherosclerosis (publishedVersion, cc-by)
PubMed (publishedVersion)
Funders: European Commission
Karolinska Institutet
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Keywords: type 2 diabetes, atherogenesis, lipoprotein metabolism, atherosclerotic cardiovascular disease, apolipoprotein B, small dense LDL, hypertriglyceridemia, HDL cholesterol, triglyceride-rich lipoproteins, insulin resistance, atherosclerotic plaque formation, plaque destabilization, cardiovascular risk assessment, cardiometabolic disease
MeSH terms: Animals, Diabetes Mellitus, Type 2, Humans, Insulin Resistance, Lipoproteins, Biomarkers, Dyslipidemias, Atherosclerosis, Plaque, Atherosclerotic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Modification of lipoprotein metabolism and function driving atherogenesis in diabetes

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks